Cell therapy for cartilage repair.
Cell therapy for cartilage repair.
复制标题
DOI：
10.1042/etls20210015
复制
发表时间：
2021-10-29
影响因子：
3.8
通讯作者：
Roberts S
中科院分区：
文献类型：
--
作者：
Hulme CH;Perry J;McCarthy HS;Wright KT;Snow M;Mennan C;Roberts S
再生医学，利用细胞作为治疗剂，用于修复或再生组织和器官，为医学的未来带来了巨大的希望。用于治疗关节软骨缺陷的细胞疗法一直是将这项技术转化为临床的典范，但它并非没有挑战。这些措施包括将为药剂设计的规章适用于活细胞。此外，与使用同种异体细胞相比，使用自体细胞作为治疗剂带来了额外的成本和后勤挑战。迄今为止，用于治疗关节中的软骨缺损或骨软骨缺损的主要细胞类型是源自各种来源如骨髓、脂肪组织或脐带的软骨细胞和间充质基质细胞。这篇综述在描述这一领域最相关的临床试验之前，讨论了它们的一些生物学和临床前研究。
Regenerative medicine, using cells as therapeutic agents for the repair or regeneration of tissues and organs, offers great hope for the future of medicine. Cell therapy for treating defects in articular cartilage has been an exemplar of translating this technology to the clinic, but it is not without its challenges. These include applying regulations, which were designed for pharmaceutical agents, to living cells. In addition, using autologous cells as the therapeutic agent brings additional costs and logistical challenges compared with using allogeneic cells. The main cell types used in treating chondral or osteochondral defects in joints to date are chondrocytes and mesenchymal stromal cells derived from various sources such as bone marrow, adipose tissue or umbilical cord. This review discusses some of their biology and pre-clinical studies before describing the most pertinent clinical trials in this area.